Key Highlights
- Medicare Part B payment rate granted for CompuFlo® Epidural System.
- Coverage includes JL (Delaware, DC, Maryland, NJ, PA) and JH (Arkansas, CO, LA, MS, NM, OK, TX) regions.
- Addresses approximately one-third of total ESI procedures for chronic back pain in the US.
- Represents an initial addressable market of ~$250 million.
- Enhances accessibility and patient outcomes, supporting healthcare providers.
Source: Globe Newswire
Notable Quote
- “Securing Medicare price assignment for the CompuFlo® Epidural System in these additional states is a testament to the clinical value and safety of our technology. This approval by Novitas significantly expands our addressable market and enhances our ability to provide patients with safer, more comfortable epidural procedures.” — Arjan Haverhals, CEO and President at Milestone Scientific
SoHC's Take
The recent Medicare Part B payment rate approval for Milestone Scientific’s CompuFlo® Epidural System represents a significant milestone in the company’s strategic expansion. This approval not only validates the clinical efficacy and safety of the CompuFlo® technology but also substantially increases its accessibility to a broader patient demographic. By ensuring accurate needle placement, the CompuFlo® Epidural System enhances patient outcomes and satisfaction, reducing risks associated with traditional epidural techniques. Moreover, the financial support provided by Medicare reimbursement will empower healthcare providers to offer advanced pain management solutions without economic constraints, ultimately improving the standard of care for chronic back pain patients. This development underscores Milestone Scientific’s commitment to pioneering medical advancements and expanding their market presence both nationally and internationally.
